



## Advances in Parasite Vaccines

Guest Editor:

### Dr. Gunjan Arora

Section of Infectious Diseases,  
Yale School of Medicine, Yale  
university, New Haven 06519, CT,  
USA

Deadline for manuscript  
submissions:

**closed (30 September 2022)**

### Message from the Guest Editor

Dear Colleagues,

Several Parasites lives on or in the human or other animal hosts and cause many serious diseases. In humans, the three main classes of disease-causing parasites are protozoa, helminths, and ectoparasites. Among Protozoan parasites, malaria, caused by the Plasmodium parasite, remains one of the most significant public health problems. The elimination of parasite diseases such as malaria will probably ultimately depend on the development of combining multiple vaccines with the partial efficacy of targeting different stages of infection. To discuss recent advances in the vaccine against various parasitic disease including malaria, , leishmania, Toxoplasmosis, trypanosomiasis, babesiosis, chagas disease, and others parasitic diseases, we invite you to contribute to Special Issue “Advances in Parasite Vaccines”. The issue will also encompass studies underlying immunity to the parasites that cause these diseases. This Special Issue will feature articles related to parasite vaccines, adjuvants, systems immunology, structural vaccinology, computational tools and new approaches, and nanoparticle- and host-directed therapy to boost vaccine efficacy.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)